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ABSTRACT 
THE ASSOCIATION BETWEEN DENGUE VIRUS INFECTION AND LIVER 
AND KIDNEY FUNCTION AMONG CAMBODIAN CHILDREN 
MAY 2020 
ASHLEY A. MOINEAU, B.S., UNIVERSITY OF MAINE ORONO 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Andrew A. Lover 
 
 Severe liver and kidney dysfunction are prevalent in 10%-30% of the Southeast 
Asian population. Dengue virus infection has been reported as a modifiable risk factor for 
liver and kidney dysfunction, especially among children in Southeast Asia. 
Epidemiologic studies assessing this relationship are sparse, often failed to include 
children, and did not adjust for important covariates. Therefore, we evaluated the 
relationship between dengue virus infection and liver and kidney dysfunction among 
hospitalized children in Cambodia (n=551). Participants with a serologically confirmed 
dengue virus infection were categorized according to increasing severity of infection (i.e. 
dengue fever, dengue hemorrhagic fever, or dengue shock syndrome) using clinical 
assessment. Laboratory assays were used to assess liver (i.e. albumin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and total protein) and kidney 
protein levels (i.e. creatinine and urea). Descriptive statistics were used to assess the 
impact of severity of dengue virus infection on kidney dysfunction. Additionally, 
descriptive statistics and linear mixed modeling were used to assess the impact of 
severity of dengue virus infection on liver dysfunction while adjusting for important risk 
factors. Approximately 75% of all participants had abnormal liver or kidney protein 
 v 
level(s) over the first four days of follow-up. Overall, a negative association was 
observed between increasing dengue disease severity and albumin (ßadj = -0.08, 95% CI = 
-0.45 to 0.29), ALT (ßadj = -18.02, 95% CI = -51.59 to 15.55), and AST (ßadj = -7.18, 95% 
CI = -49.57 to 35.21) protein levels. A positive association was observed between 
increasing dengue disease severity and total protein levels (ßadj = 7.14, 95% CI = 1.15 to 
13.13). While abnormal liver function (increases in ALT and/or AST levels and decreases 
in albumin and/or total protein levels) is a common clinical finding in dengue infections,  
we did not find evidence for a significant association with more severe forms of dengue 
virus infection (i.e. dengue hemorrhagic fever or dengue shock syndrome) and greater 
liver dysfunction as compared to patients with dengue fever in pediatric populations in 
Cambodia. 
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CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
 
A. Introduction 
 Liver and kidney dysfunction are general terms that refer to the improper 
functioning of the liver or kidneys. Liver (hepatic) and kidney (renal) dysfunction are 
characterized by certain traumatic damages to the filtering properties of these organs, 
often known as liver or kidney diseases and disorders. Common liver diseases and 
disorders include liver cirrhosis (scarring), liver inflammation, and non-alcoholic fatty 
liver disease (NAFLD), all of which can ultimately result in liver failure. Common 
kidney diseases and disorders include glomerulonephritis and interstitial nephritis, where 
the filtering units of the kidneys are dysfunctional. This often results in urine back-up in 
the kidneys, or in severe cases, kidney failure. Recent studies have estimated that liver 
and kidney disease impacts between 4.5% to 9.5%1 and 8% to 10% of the population 
worldwide, respectively.2 In Southeast Asia, these numbers vary markedly with 30% of 
the population estimated to have some form of fatty liver disease (a general term to 
describe the build-up of fat in the liver, liver inflammation, liver scarring, and/or liver 
failure).3-4 There is an estimated incidence rate of 63 new fatty liver disease cases per one 
million people in Southeast Asia diagnosed per year.5 Chronic kidney diseases are 
present in 10% to 20% of the population in Southeast Asia, with an estimated incidence 
rate of 200 to 300 new cases per one million people diagnosed per year.6 Reporting for 
prevalence and incidence of liver and kidney disease are believed to be underestimates, as 
these syndromes are often clinically silent, and therefore, under-diagnosed.   
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 Dysfunction of the liver or kidney can lead to more severe health issues such as 
liver failure, kidney failure, and death. Liver and kidney dysfunction can arise from 
various underlying health issues, especially in children, including genetic predisposition, 
autoimmune disorders, obesity, and persistent infection.7,8  
 Non-modifiable risk factors for liver dysfunction include inherited genetic 
conditions. One example is Alpha-1-antitrypsin deficiency (AATD), a disorder 
characterized by liver scarring, severe liver dysfunction, and often liver failure. AATD 
occurs in individuals who have two non-functional copies (“ZZ”) within an exon of the 
SERPINA1 gene that encodes the alpha-1 antitrypsin protein. Another example of an 
inherited genetic condition that can result in liver dysfunction is Wilson’s disease.9 
Individuals diagnosed with Wilson’s disease often experience liver scarring followed by 
gallstones, acute hepatitis, and liver failure as a result of mutations in the ATP7B gene.9 
 Common non-modifiable risk factors for serious kidney dysfunction among 
children include birth defects, such as renal dysplasia when the kidneys do not properly 
develop during fetal growth10, and inherited genetic diseases, including Alport syndrome 
where mutations in the COL4A3 and/or COL4A4 genes often lead to end-stage renal 
disease.10,11  
Among the most common modifiable risk factors for liver disease among children 
are obesity and viral hepatitis (HAV, HBV, or HCV).9 Obesity has become a growing 
issue in children throughout the world, and is the leading cause of non-alcoholic fatty 
liver disease in children.9 Chronic kidney disease in children is also often caused by 
modifiable factors such as diabetes and bacterial or viral infections.10,11 
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 A potential risk factor for both liver and kidney dysfunction among children in 
Southeast Asia is dengue virus infection.12,13 14 Infections with this arbovirus vary greatly 
by severity and clinical course, and can be categorized into three disease categories listed 
in order of increasing severity: dengue fever (DF), dengue hemorrhagic fever (DHF), and 
dengue shock syndrome (DSS).15,16 As defined by WHO 1997 and 2009 dengue infection 
classification guidelines, the severity level of a dengue virus infection is characterized by 
various clinical factors,32 as listed in Table 1. The 1997 WHO guidelines rely mainly on 
patient observational assessments, whereas the 2009 guidelines utilize both observational 
assessments as well as laboratory analyses (e.g. platelet counts, hematocrit 
measurements), and are most suitable for well-resourced health facilities.32  
Four strains of dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4) are 
known to cause infections in humans, but all produce similar symptomatology among 
infected patients.16 An outbreak of dengue viral infections occurring in areas of Southeast 
Asia led to the diagnosis of over 100,000 cases of dengue virus infection in 2016 alone.17 
Although the proportion of children among cases in this outbreak cannot be ascertained 
from WHO reports, data suggest that dengue virus infection is most common among 
populations less than 15 years of age, especially in endemic areas such as Cambodia due 
to childrens’ immature immune systems. While the direct physiological relationship 
between dengue virus infection and dysfunction of specific organs such as the liver and 
kidneys has not yet been fully characterized, it has been suggested that dengue virions 
may invade the liver and kidneys, potentially directly impairing liver and/or kidney 
function. This study therefore proposes to investigate the relationship between dengue 
disease severity as measured by disease category and risk of liver and kidney 
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dysfunction, as indicated by blood protein values, among a cohort of Cambodian children 
using clinical data collected between September 2011 and January 2013.  
 
B. Physiology of the Relationship between Dengue Virus Infection and Abnormal 
Liver and Kidney Function 
 The direct physiological relationship between dengue virus infection and liver and 
kidney dysfunction has not yet been fully characterized, however one potential 
mechanism has been proposed: direct dengue virus invasion into liver and kidney tissue. 
Dengue virus may directly invade and infect the liver and kidneys, leading to the 
pathogenesis of liver and kidney disorders.12,13,16 Recent studies have proposed that, in 
response to dengue virus infection, the increased presence of Natural Killer (NK) cells in 
the liver and increases in interleukin-10, interleukin-17, and interleukin-22 are believed 
to contribute to hepatic cell apoptosis.12,16 Viral invasion of the liver and kidneys can lead 
to hepatic sinusoidal obstruction, or the damage and death of endothelial cells in the 
liver,18 as well as deposition of immune complexes within kidney cells.13  
 Recent or concurrent use of hepatotoxic drugs among dengue-infected individuals 
has also been shown to modify the effects of dengue virus infection on liver cells.19 By 
definition, hepatotoxic drugs are known to negatively impact liver function,20 and they 
can worsen the effects of dengue virus infection on liver function.17,18 Hepatotoxic drugs 
include antibiotics and antiviral medications as well as commonly used anti-inflammatory 
medications (e.g. non-steroidal anti-inflammatory drugs) including pain/fever relievers 
(e.g. acetaminophen).21  
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C. Epidemiology of the Relationship between Dengue Virus Infection and Liver and 
Kidney Function 
 Five prior epidemiological studies have evaluated the relationship between 
dengue virus infection and liver and/or kidney function.22-26 Four of these studies utilized 
a retrospective cohort design;22,23,24,25 while the remaining study was a prospective 
cohort.26 Two of the five studies included children in their study populations,23,25 one of 
which included a population of children from Southeast Asia.25 Epidemiologic studies 
assessing the relationship between severity of dengue virus infections and liver and 
kidney function are essential in order to properly monitor individuals with a dengue virus 
infection through the duration of their illness.  
Only a single study analyzed blood creatinine and urea levels, which serve as 
indicators of kidney function;22 while the other studies23, 24, 25, 26 performed analyses of 
only blood liver protein levels (i.e. ALT, AST). In the study that assessed kidney protein 
levels by Wilder-Smith et al., adult patients diagnosed with dengue virus infection were 
compared to those diagnosed with severe acute respiratory syndrome (SARS) as the 
unexposed reference category.22 Therefore, the authors did not use a three-level exposure 
of dengue disease severity in order to assess differences among dengue severity levels 
alone.22 All five studies found that among patients with more severe dengue virus 
infections, an apparent increase in ALT and AST levels was found.22-26  
In the only study to include children in their study population and also evaluate 
severity of dengue disease as the exposure of interest, Lee et al. utilized a retrospective 
cohort study design to analyze clinical records of 690 patients.23 Adult and pediatric 
patients who presented to the Department of Infectious Diseases at Tan Tock Seng 
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Hospital in Singapore and tested positive for dengue virus infection between 2006 and 
2008 were included in the analysis. Exposure was classified by dengue disease severity 
(DF, DHF, or DSS) based on the 1997 and 2009 WHO classification systems. Blood 
ALT and AST levels, which serve as indicators of liver function were extracted from 
patient records for outcome assessment. The median AST levels among DF, DHF, and 
DSS individuals were 93.0, 103.0, and 137.5 U/L, respectively. The median ALT levels 
among DF, DHF, and DSS individuals were 52.0, 60.0, and 74.0, respectively. 
Statistically significant increases in AST levels (p= 0.01) were observed, from Mann-
Whitney U and Kruskal-Wallis tests, among patients categorized as having DSS, as 
compared to those with DF. This indicates that increasing severity of dengue disease was 
associated with an increased risk of liver dysfunction. This study by Lee et al. however 
did not stratify results by age to see if changes in ALT and AST levels differed between 
adults and children. These researchers also did not review indicators of kidney function 
(i.e. creatinine and urea).    
In summary, all five epidemiological studies were limited in regard to study 
population, as only two23,25 of the five22-26 studies included children. Four studies 
examined the association between stages of dengue disease severity and liver   
function,23-26 but only one study22 assessed the impact of dengue disease severity on 
kidney protein levels. No covariates were assessed or included in the analyses of any of 
the five studies,22-26 likely resulting in biased association measures due to uncontrolled 
confounding, particularly by age and recent non-steroidal anti-inflammatory drugs 
(NSAID) use.  
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D. Study Objectives, Significance and Innovation 
This study proposes to assess the relationship between dengue disease severity as 
measured by disease category and risk for liver and kidney dysfunction, as measured by 
changes in blood protein levels, adjusting for multiple clinical factors. Specifically, the 
aim of the study is: 
Specific aim: Use data collected from pediatric patients in Phnom Penh, 
Cambodia to evaluate the relationship between dengue disease severity 
classification and liver and kidney protein laboratory levels.  
Hypothesis 1: Children diagnosed with more severe disease (dengue hemorrhagic 
fever and dengue shock syndrome) will have statistically significant differences in 
liver function, defined by higher mean blood ALT and AST levels and lower 
mean blood albumin and total protein levels, as compared to children who have 
dengue fever.   
Hypothesis 2: Children diagnosed with more severe disease (dengue hemorrhagic 
fever and dengue shock syndrome) will have statistically significant differences in 
liver function, defined by higher mean blood creatinine and urea protein levels, as 
compared to children who have dengue fever. 
These analyses will contribute to the sparse epidemiological findings on the association 
between dengue virus infection among children in Southeast Asia and liver/kidney 
function.  
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This study is innovative because it is the first, to our knowledge, to analyze 
longitudinally the association between dengue disease severity and liver and kidney 
dysfunction among children in Cambodia. It is also innovative in its ability to adjust for 
multiple covariates, due largely to the prospective study design.  
 This study is significant because it utilized an under-studied population at 
increased risk for both the exposure and outcome. Few studies have looked at the 
association between dengue disease severity and risk of liver and kidney dysfunction 
among children, and this study can contribute to a more comprehensive understanding of 
the relationship between dengue virus infection and kidney and liver function in pediatric 
populations.  
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CHAPTER II 
STUDY DESIGN AND METHODS 
 
A. Study Design and Population 
 We evaluated the relationship between dengue disease severity and liver and 
kidney function among children from the Cambodian Dengue study: a prospective cohort 
study conducted between September 20, 2011 and January 15, 2013.27 Participants were 
enrolled at the National Paediatric Hospital (NPH), Phnom Penh, Cambodia. All children 
aged 1-15 years presenting to the internal medicine or emergency wards of the NPH with 
a current fever or history of fever in the last seven days were initially considered as 
potential participants for this study upon their admission to NPH. Children were eligible 
to participate if they met either the 1997 or 2009 WHO criteria for dengue viral 
infection.15,16 The exclusion criteria for the Cambodian Dengue study has been described 
previously,27 and included no indication of fever or history of fever in the last week upon 
admission, and eligibility forms assessing clinical symptoms not being completed. Of the 
1,228 children who were initially screened for inclusion, 704 participants were 
considered eligible due to information obtained from eligibility forms that clinically 
assessed patient symptoms using WHO 1997 and 2009 dengue case definitions. 
Ultimately, 704 children met eligibility requirements, consented to participation in the 
study, and were included in the final dataset.  
Of these 704 participants included in the dataset, this analysis excluded 146 who 
were serologically negative for a dengue virus infection. Additionally, 12 participants 
were excluded due to missing WHO 1997 dengue infection classifications. This resulted 
in a final analytic population of 551 participants (Table 3).  
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Clinical and demographic data were collected from all enrolled participants at 
time of admission by NPH staff. Blood samples for liver and kidney protein analyses 
were collected from children upon admission and for each subsequent day of hospital 
stay, for up to seven consecutive days. All virological and serological blood assays were 
performed at the virology department of Institut Pasteur in Phnom Penh, Cambodia; all 
routine clinical laboratory analyses were performed at NPH. 
Ethics: The study was conducted according to the ethical principles of the 
Declaration of Helsinki of October 2002. The Cambodian National Ethics Committee for 
Health Research approved the overall study protocol after institutional review (approval 
number 123-NECHR, 22 August 2011), with fully informed consent in Khmer for all 
participants and/or guardians. 
 
B. Exposure Assessment 
 Blood samples were collected from all eligible participants upon admission and 
were immediately centrifuged. Serum samples were shipped the same day for serologic 
and virologic testing for dengue virus infection and other potential arboviral infections. 
Serologic testing for infection included IgG / IgM Capture ELISA and hemagglutination 
inhibition assays. Virologic testing was performed through direct virus isolation, RT-
PCR, and NS1 antigen detection by ELISA. A combination diagnostic kit that detects 
NS1 antigen and IgM and IgG antibodies was also utilized. Participants who tested 
negative for dengue virus infection by virological and serological testing were excluded 
from the analyses. 
 NPH staff utilized clinical assessment to classify patients by severity of dengue 
virus infection using both the 1997 and 2009 WHO classification systems, upon patient 
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admission to NPH.15,16 Patients presenting with symptoms of a dengue virus infection 
were classified into one of three disease categories based on clinical judgement: DF, 
DHF, or DSS.  
 Subsequently, the results of serologic and virologic blood assays, as well as 
clinical assessment criteria using the 1997 WHO dengue classification system were 
applied to categorize participants by exposure status into three severity categories (DF, 
DHF, or DSS) for our categorical severity variable. Due to small cell frequencies, a 
second categorical variable was created for multivariable analyses that categorized 
participants by dichotomous disease severity categories. In other words, participants were 
categorized as having severe dengue if they were clinically diagnosed with DHF or 
DSS.    
 The combination diagnostic test kit used in this study has been shown to be valid 
for detecting dengue virus infection by NS1 antigen and IgM and IgG antibodies. In a 
field validity study, Andries et al. found a sensitivity of 85.7% (95% CI: 78.4 to 91.3), 
specificity of 83.9% (95% CI: 66.3 to 94.5), positive predictive value (PPV) of 95.6% 
(95% CI: 90.0 to 98.5), and a negative predictive value (NPV) of 59.1% (95% CI: 43.2 to 
73.7) for dengue virus infection among hospital laboratories in Cambodia. Additionally, 
the national reference laboratory at Institut Pasteur (Cambodia) found the sensitivity, 
specificity, PPV, and NPV of the combination diagnostic kit for dengue virus infection to 
be 94.4% (95% CI: 88.9, 97.7), 90.0% (95% CI: 73.5, 97.9), 97.5% (95% CI: 93.0, 99.5), 
and 77.1% (95% CI: 59.9, 89.6), respectively.28 When used in conjunction with clinical 
assessment of symptoms, false negative results were not found to impact patient 
management.     
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 The RT-PCR method used to detect the dengue virus has been well-validated in 
prior studies. In a validity study by Hue et al., the limit of detection (LOD) and 
specificity of RT-PCR for dengue RNA detection and quantification in human blood 
samples was assessed.29 The specificity for both viral particle and plasmid DNA 
amplification was 100%. The authors concluded the RT-PCR method had good 
sensitivity for all four strains of dengue virus.  
 Mosquito C6/36 and Vero E6 cell lines were used for direct viral culture in this 
study; the validity of this procedure has been described elsewhere and is a widely used 
technique for directly identifying the presence of virus in culture.30  
 
C. Outcome Assessment 
 Blood was collected from all participants upon admission and for up to seven 
consecutive days, or until discharge. Liver protein levels assessed included serum ALT, 
AST, albumin, and total protein. Kidney protein levels measured included serum 
creatinine and urea levels.  
Additionally, liver and kidney protein levels were categorized into normal and 
abnormal values, by sex, using the cut-off points for abnormal laboratory values shown in 
Table 2. These cut-off points for high versus low values have been adapted from The 
Harriet Lane Handbook, 21st Edition.31  
D. Covariate Assessment 
 Risk factors associated with both dengue virus infection and with abnormal liver 
and kidney function were assessed as possible confounders. These covariates included: 
age, sex, body mass index (BMI), recent NSAID use, clinical diagnosis of influenza-like 
illness (ILI) or acute respiratory illness (ARI), confirmed diagnosis of malaria or 
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chikungunya, prior dengue virus infection, time of fever onset prior to admission, 
infusion prior to admission, and all blood parameters collected (i.e. complete blood count, 
glucose level, sodium level).7-11, 31 Data for age, height and weight (used to calculate 
BMI), and sex were collected upon patient admission to NPH. Clinical diagnosis of 
ILI/ARI, malaria, or chikungunya were determined from lab data collected at patient 
discharge. Prior use of NSAIDs was self-reported upon admission, and NSAID use on 
each day of hospitalization was also documented daily by NPH staff for 12 consecutive 
days or until discharge. Prior dengue virus infection, time of fever onset prior to 
admission (days), and infusion prior to admission were self-reported by participants, or 
guardians, at time of admission. Blood count parameters such as leukocyte and platelet 
counts were analyzed upon admission, and on each day of hospitalization for 12 
consecutive days or until discharge. Blood glucose, sodium, potassium, and calcium 
levels were analyzed only upon admission.  
 
 
 
 
 
 
 
 
 
 
 14 
CHAPTER III 
DATA ANALYSIS 
Specific aim: Use data collected from pediatric patients in Phnom Penh, Cambodia to 
evaluate the relationship between dengue disease severity and liver and kidney protein 
levels.  
 All statistical analyses were conducted using SAS version 9.4. Multiple 
imputation was conducted to account for missing data among all covariates as well as 
among the liver and protein outcome measures. This multiply imputed dataset was used 
for multivariable model building only. The significance of each of the four multivariable 
models was assessed using Wald tests for model fit.      
A. Descriptive Analysis 
 The total number and percent of study participants who tested negative for dengue 
virus infection and the number and percent of those missing dengue disease severity 
classification using 1997 WHO guidelines was assessed. The number and proportion of 
those diagnosed with DF, DHF, and DSS by clinical assessment was also calculated. The 
mean and SD of liver protein levels (i.e. albumin, ALT, AST, and total protein) and 
kidney protein levels (i.e. creatinine and urea) were calculated for up to seven days of 
follow up. The distribution of all continuous laboratory analyses (e.g. liver and kidney 
protein levels, complete blood counts, etc.) followed normal distributions, and therefore 
did not require transformation of values. 
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B. Bivariate Analysis 
 Cross-tabulations of all covariates by both our exposure (dengue disease severity 
assessed by clinical assessment) and our outcome (liver and kidney protein levels) were 
performed. Chi-square (Χ2) tests were used to calculate p-values for categorical variables. 
Where small cell frequencies (n<5) were encountered, the Fisher’s Exact Test was 
utilized. To calculate p-values for our continuous variables, ANOVA was used.  
 
C. Multivariable Analysis 
 Linear mixed modeling was used to model the relationship between dengue 
disease severity and abnormal liver protein levels for a total of seven days of patient 
hospital admission. Due to the small number of participants with values for kidney 
protein outcomes (creatinine and urea levels) analyzed in this cohort, multivariable 
regression analyses were performed only for liver protein outcomes (i.e. albumin, ALT, 
AST, and total protein). Separate models were created for each of the four continuous 
liver protein metrics. Covariates included in the model that caused a 20% change in the 
coefficient for dengue disease severity were considered as confounding variables and 
were included in all final models. Unadjusted and adjusted coefficient estimates are 
reported with corresponding 95% confidence intervals.  
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CHAPTER IV 
RESULTS 
 
Characteristics of the study participants are described in Table 6. Of the 551 
participants included in this study, 456 (82.8%) were clinically diagnosed with DF, 91 
(16.5%) were diagnosed with DHF, and 4 (0.7%) were diagnosed with DSS. The mean 
age (SD) of children in this cohort for those diagnosed with DF, DHF, and DSS was 7.9 
(3.38), 8.43 (3.82), and 5.5 (1.29), respectively (ANOVA: p= 0.15). Those clinically 
diagnosed with more severe forms of dengue (i.e. dengue hemorrhagic fever or dengue 
shock syndrome) had significantly lower platelet counts upon admission to NPH, as 
compared to those diagnosed with dengue fever (p<0.001).  Although only one 
participant diagnosed with DSS had their sodium level analyzed upon admission, this 
value was significantly lower than the mean sodium levels among those diagnosed with 
DF or DHF (p=0.04). There was no evidence for differences in any of the other examined 
covariates compared across the three levels of dengue disease severity (Table 6). 
 Results from the liver protein laboratory analyses are presented in Tables 4, 7 and 
8. Overall, upon admission a significantly greater proportion of those diagnosed with DF 
had abnormal ALT and AST protein levels (both with p <0.0001; Table 4). Similarly, a 
significantly higher percentage of those diagnosed with DHF had abnormal ALT and 
AST levels upon admission (both with p<0.0001; Table 4). Participant liver protein levels 
at admission were more likely to be abnormal (81.0 to 100% of all participants) with the 
exception of total protein, which was more likely to be within the normal range (Table 7). 
The mean age (SD) of those with abnormal albumin, ALT, AST, and total protein levels 
was 9.33 (3.06), 7.99 (3.42), 8.02 (3.40), and 7.28 (3.03), respectively (Table 8). A higher 
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percentage of those with abnormal ALT levels upon admission were female (52.7%; 
p=0.0005), however no statistically significant differences between participant sex were 
observed for any other liver or kidney protein outcome (Table 8). Additionally, 
participants with abnormal total protein levels at admission were significantly more likely 
to have had an infusion prior to admission (67.8%; p=0.0007); have a significantly lower 
platelet count (p<0.0001) and mean corpuscular volume (p=0.012); and have a 
significantly higher hematocrit percent (p=0.045) and hemoglobin value (p=0.025; Table 
8). No other statistically significant differences in participant characteristics were 
observed across the four liver protein outcomes (Table 8). 
 Results from the kidney protein laboratory analyses are presented in Tables 5, 7, 
and 9. Few participants had their creatinine (n=6) or urea (n=3) levels measured upon 
admission (Table 5). However, among those with measurement values, creatinine levels 
were more likely to be abnormal (100%) and urea levels were more likely to be normal 
(100%; Table 7). Because of the small number of participants with kidney protein level 
measurements, statistical differences in creatinine and/or urea levels by participant 
characteristics could not be assessed (Table 9).  
In general, over the seven days of follow-up, the absolute number (Fig. 1) and 
percent (Fig. 2) of those with any abnormal liver protein level who were diagnosed with 
DF was greater than that of those diagnosed with severe dengue (dengue hemorrhagic 
fever or dengue shock syndrome). However, a larger proportion of participants with 
severe dengue had at least one abnormal liver protein measure on days 2 (DF: 12.72%, 
severe dengue: 31.58%), 4 (DF: 2.19%, severe dengue: 5.26%), and 5 (DF: 0%, severe 
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dengue: 2.11%). Few participants had protein measurements taken on days 4-7; thus, 
these results should be interpreted with caution.  
Day1 (day of admission) through day 3 of hospital stay contained the largest 
number of participants with analyzed ALT and AST levels. Upon admission and on day 2 
of hospital stay, the average ALT (Figure 5) and AST (Figure 6) levels remained 
consistent, around 85-90 IU/L. On day 3 of hospital stay, the average protein levels were 
seen to decrease significantly to around 50 IU/L for both ALT (Figure 5) and AST 
(Figure 6) levels. High variation was observed for ALT and AST protein levels analyzed 
on all days of hospital stay among those clinically diagnosed with DF compared to those 
clinically diagnosed with severe dengue (Figure 5 and Figure 6), likely due to the 
significantly larger number of participants in the DF exposure category. 
 None of the participants with dengue fever had measurement values for creatinine 
or urea. However, a distribution of the absolute number (Figure 3) and proportion (Figure 
4) of participants with severe dengue who had at least one abnormal kidney protein value 
on each of the seven days of follow up are presented. A clear increase in the number of 
individuals (11) with severe dengue who had abnormal kidney protein level(s) is 
observed on day two of hospital stay.   
 Table 10 shows the associations between dichotomized dengue disease severity 
and liver protein outcomes. We observed a significant increase in mean total protein level 
among those diagnosed with severe dengue as compared to those diagnosed with dengue 
fever in both unadjusted and adjusted models (Βadj = 7.14, 95% CI = 1.15 to 13.13). We 
also observed a significant decrease in mean albumin levels among participants with 
severe dengue disease compared to those with dengue fever; however, this association 
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became insignificant following adjustment for covariates (Βadj = -0.08, 95% CI = -0.45 to 
0.29). Finally, we also observed a nominally significant decrease in the mean ALT and 
AST protein levels among those diagnosed with severe dengue as compared to those 
diagnosed with dengue fever (ALT: Βadj = -18.02, 95% CI = -51.59 to 15.55; AST: Βadj = 
-7.18, 95% CI = -49.57 to 35.21). Because of the small sample size, we were not able to 
evaluate the association between dengue severity and creatinine or urea protein levels in a 
fully-adjusted analysis. 
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CHAPTER V 
DISCUSSION 
 
 In this prospective cohort study of pediatric dengue virus infections in Cambodia, 
descriptive statistics were used to assess the impact of severity of dengue virus infection 
on kidney dysfunction. Additionally, descriptive statistics and linear mixed modeling 
were used to assess the impact of severity of dengue virus infection on liver dysfunction 
while adjusting for important risk factors. We observed one statistically significant 
positive association between dengue disease severity and total protein levels. Three non-
significant inverse associations were observed between dengue disease severity and 
albumin, ALT, and AST protein levels. Although it was not possible to assess an 
association between dengue disease severity and kidney protein levels using 
multivariable models, a large proportion of those diagnosed with severe forms of dengue 
virus infections had abnormal creatinine and urea levels on each day of hospital stay, 
with an apparent increase in the number and percent of participants with abnormal levels 
on day 2 of hospital stay.  
 There are few epidemiological studies that have assessed the quantitative 
association between severity of dengue virus infection and liver protein outcomes23, 24, 26 
and even fewer that have assessed an association with kidney protein outcomes.22 All 
three studies that specifically examined severity of dengue virus infections and the 
association with liver protein outcomes found statistically significant increases in either 
the median or the mean ALT and AST levels among those diagnosed with more severe 
forms of dengue virus infection, compared to those diagnosed with DF throughout the 
duration of hospital stay. However, in general, the previous studies had significantly 
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larger populations and comprehensive follow-up data available for a minimum of 10 days 
of hospital stay, whereas the present study analyzed lab values collected for up to seven 
days of follow-up. Two studies24, 26 excluded participants less than 14 years of age, 
limiting their analyses to a population that is comparatively older (mean age: 21 and 
26.4) than our study population. The third study23 included a population of adults and 
children, however the mean age of the population was 35 years. The mean age of 
participants in our study was 8 years for those diagnosed with DF or DHF and 6 years for 
those diagnosed with DSS. Because our study is the first to look at an exclusively 
pediatric population, our results may provide age-specific association measures between 
dengue disease severity and liver and kidney dysfunction.  
   We observed an overall decrease in average ALT and AST levels and an 
increase in average total protein levels among those diagnosed with more severe forms of 
dengue virus infections as compared to those diagnosed with DF. Because liver 
dysfunction is characterized in part by increases in ALT and AST levels and decreases in 
total protein levels, our results do not suggest an overall increase in liver dysfunction 
among those clinically diagnosed with severe forms of dengue virus infections (i.e. DHF 
or DSS) compared to those clinically diagnosed with DF. Despite the small number of 
participants with measured albumin levels, we did observe a decrease in the mean 
albumin level over the 7 days of follow up among those clinically diagnosed with severe 
dengue compared to those clinically diagnosed with DF. Although statistical significant 
effects were not found in this study, these results are consistent with previous 
literature23,24,26 and suggest potential for decreased liver function among those with more 
 22 
severe forms of dengue virus infections, as blood albumin levels are known to decrease in 
response to liver dysfunction.  
This study is not without limitations. One important limitation is loss to follow 
up. Studies involving the prospective collection of hospital data are prone to differential 
loss of participants based on patient diagnosis, symptomatology, and overall patient 
health. The large proportion of missing data in the present study suggest that participants 
were either discharged from NPH at different time points or passed away. Those with less 
severe dengue virus infections (i.e. DF) who had adequate liver and kidney function were 
likely discharged from the hospital sooner than those who had more severe forms of 
dengue virus infections and/or impaired liver and kidney function. This form of 
differential loss to follow up would result in an attenuation of any measured association. 
Non-differential misclassification of participant outcome could have also occurred 
in our study, leading to an underestimation of the association between dengue disease 
severity and liver and kidney dysfunction. Participants were diagnosed with DF, DHF, or 
DSS using clinical judgement alone, therefore children in this study could have been 
incorrectly classified if their symptomatology was difficult to assess.  
The time of patient admission to NPH does not necessarily correlate with time of 
infection with dengue virus, or time of disease onset (i.e. DF, DHF, DSS) in our study. 
Children admitted to NPH may have had, in general, more severe cases of dengue virus 
infection compared to the general pediatric population. It is also possible that children 
initially diagnosed with DF upon admission developed more severe symptoms later in 
their hospital stay. This would have incorrectly classified patients as having DF, whose 
data actually represent someone with DHF or DSS. It is also possible that severely ill 
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patients admitted to NPH who were initially classified as having DHF or DSS improved 
during their hospital stay, and had characteristics that were more closely related to a 
diagnosis with DF. This could have also misclassified participants in our study later in 
their hospital stay.    
Despite the potential limitations, our study has several strengths. The prospective 
study design and collection of follow-up data limit the potential for biases such as recall 
bias or temporal bias that are common in other study designs. Our ability to adjust for 
multiple covariates makes our study unique from other studies that also looked at severity 
of dengue virus infections and liver and kidney dysfunction, and allows us to report a 
multivariable-adjusted effect estimate comparing those diagnosed with DF with those 
diagnosed with more severe forms of dengue virus infection. Our study population was 
also an under-studied, but high-risk, cohort of children in Southeast Asia.  
Overall, the present study found that those diagnosed with more severe forms of 
dengue virus infections have lower average albumin, ALT, and AST protein levels and 
higher average total protein levels when compared to those diagnosed with a less severe 
dengue virus infection. Overall, this is not suggestive of large increases in liver 
dysfunction among those clinically diagnosed with severe dengue virus infections, 
compared to those diagnosed with DF. A large percentage of those with severe dengue 
virus infections were also observed to have abnormal kidney protein levels (creatinine or 
urea). Although only one of our effect estimates reached statistical significance, it is 
important to note the significant loss to follow up for liver and kidney protein levels that 
reduced the analytic population size for each subsequent day of hospital stay. This study 
provides preliminary results that lay the groundwork for future studies assessing the 
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association between dengue disease severity and liver and kidney function among 
children. Further studies utilizing larger populations of children and comprehensive 
follow up for liver and kidney protein levels are warranted and will help explain the 
extent to which severity of dengue virus infection influences liver and kidney function 
among children with a dengue virus infection.  
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Table 1. WHO 1997 and 2009 Dengue Infection Classification Guidelines 
Clinical criteria used to classify patients by dengue disease severity, according to WHO 1997 and 2009 guidelines for dengue 
diagnosis and treatment. Information in this table was adapted from Narvaez et al. 
 
WHO Guideline Year: 1997 2009 
  
DF: Headache, myalgia, leukopenia, rash, 
hemorrhagic manifestations 
Dengue w/out Warning Signs: nausea, rash, aches, 
leukopenia, positive tourniquet test 
  
DHF: Fever or history of fever (2-7 days), 
positive tourniquet test, bleeding from various 
sites, thrombocytopenia, plasma leakage 
Dengue w/ Warning Signs: abdominal 
tenderness/pain, persistent vomiting, fluid 
accumulation, bleeding, lethargy, liver enlargement, 
increase in hematocrit, decreased platelet count  
  
DSS: All signs of DHF plus hypotension for age, 
rapid/weak pulse, cold and clammy skin 
Severe Dengue: severe plasma leakage, shock, fluid 
accumulation, respiratory distress, severe bleeding, 
severe organ involvement and failure  
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Table 2. Cut-off Points for Defining Abnormal Liver and Kidney Protein Levels; 
CDS 2011-2013, n=551 
 
Protein Abnormal values-Male 
Abnormal values-
Female  
ALT >45 IU/L >30 IU/L 
AST >40 IU/L >35 IU/L 
Albumin <36 g/L <36 g/L 
Total protein <56 g/L <56 g/L 
Urea >6.4 mmol/L >6.4 mmol/L 
Creatinine >62 µmol/L >62 µmol/L 
Cut-off points for pediatric patients, by sex, adapted from 
the Harriet Lane Handbook, 21st edition 
Abbreviations: ALT, alanine aminotransferase; AST, 
   aspartate aminotransferase; IU, international units. 
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Table 3. Number and Percent in Final Sample; CDS 2011-2013, n=551 
 
    Total Percenta 
Original Study Sample   704 100% 
        
Excluded       
Negative testing for dengue infectionb    146 20.70% 
Missing WHO 1997 dengue infection classification   12 1.70% 
        
Final Sample Size   551 77.60% 
aPercent of original population                                                                                                               
bNegative testing for Dengue infection determined by serological and virological laboratory 
assays 
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Table 4. Distribution of Dengue Disease Severity by Liver Protein Levels; CDS 2011-2013, n=551 
 
 
                                                 
Dengue Disease Severity Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
Dengue Fever 0 (0%) 0 (0%) n/a 72 (18.56%) 316 (81.44%) <0.0001*** 56 (14.43%) 332 (85.57%) <0.0001*** 285 (74.8%) 96 (25.2%) <0.0001***
Dengue Hemorrhagic Fever 0 (0%) 3 (100%) n/a 5 (8.93%) 51 (91.07%) <0.0001*** 8 (14.29%) 48 (85.71%) <0.0001*** 7 (100%) 0 (0%) n/a
Dengue Shock Syndrome 0 (0%) 0 (0%) n/a 1 (50%) 1 (50%) n/a 0 (0%) 2 (100%) n/a 0 (0%) 1 (100%) n/a
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
***p<0.0001
Normal and abonrmal liver protein levels are from admission blood analyses only. Numbers presented are total number of participants with correpsonding percent in each dengue disease severity category. Fisher's exact tests were 
used to calculate p-values, however p-values could not be calculated for comparison groups with <1 data point (indicated by value of "n/a").
Liver Protein Levels
Albumin ALT AST Total Protein
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Table 5. Distribution of Dengue Disease Severity by Kidney Protein Levels; CDS 
2011-2013, n=551 
 
 
                                                  Kidney Protein Levels 
  Creatinine     Urea 
Dengue Disease Severity Normal Abnormal     Normal Abnormal 
              
Dengue Fever 0 (0%) 0 (0%)     0 (0%) 0 (0%) 
              
Dengue Hemorrhagic Fever 0 (0%) 6 (100%)     3 (100%) 0 (0%) 
              
Dengue Shock Syndrome 0 (0%) 0 (0%)     0 (0%) 0 (0%) 
Normal and abnormal liver protein levels are from admission blood analyses only. Numbers presented are 
total number of participants with corresponding percent in each dengue disease severity category. P-values 
could not be calculated as all comparison groups contained <1 data point. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
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Table 6. Distribution of Covariates According to Dengue Disease Severity; CDS 2011-2013, n=551 
 
 
 
                                                 
Characteristics p-value
Age 0.15
Sex 0.16
Male
Female
BMIa 0.27
Underweight
Normal weight
Overweight
Obese
Prior NSAID Use 1.00
Yes
No
0.53
Yes
No
Prior Dengue Virus Infection 0.56
Yes
No
Infusion Prior to Admission 0.43
Yes
No
Leukocyte Count 0.15
Lymphocyte Count 0.07
3 (0.66%)
453 (99.34%)
1 (1.10%)
90 (98.90%)
51 (56.04%)
7 (7.69%)
6 (6.59%)
0 (0%)
0 (0%)
1 (0.22%)
454 (99.56%)
0 (0%)
Clinical Diagnosis ARI/ILI
Dengue Disease Severity
Dengue Fever (n=456) Dengue Hemorrhagic Fever (n=91) Dengue Shock Syndrome (n=4)
211 (46.27%)
2 (50.00%)
2 (50.00%)
7.90 (3.38) 8.43 (3.82) 5.50 (1.29)
236 (51.75%) 37 (40.66%) 2 (50.00%)
220 (48.25%) 54 (59.34%) 2 (50.00%)
0 (0%)
4 (100.00%)
195 (42.76%) 27 (29.67%)
1.91 (1.22) 2.26 (1.83) 1.80 (1.38)
2 (50.00%)
218 (47.81%) 53 (58.24%) 2 (50.00%)
221 (48.46%) 35 (38.46%)
91 (100%)
21 (4.61%)
28 (6.36%)
3 (0.66%)
237 (51.97%)
1 (1.10%)
51 (56.04%)
0 (0%)
3 (100.00%)
0 (0%)
4 (100.00%)
5.26 (3.00) 5.89 (3.99) 6.88 (1.76)
  
 
 
31 
Table 6. Distribution of Covariates According to Dengue Disease Severity; CDS 2011-2013, n=551 (cont.) 
 
 
 
                                                 
Characteristics p-value
Dengue Disease Severity
Dengue Fever (n=456) Dengue Hemorrhagic Fever (n=91) Dengue Shock Syndrome (n=4)
Platelet Count 0.001**
Neutrophil Count 0.69
Hemoglobin Value 0.22
Mean Corpuscular Volume 0.18
Mean Corpuscular Hemoglobin 0.85
Glucose Level 0.69
Sodium Level 0.04*
Potassium Level 0.88
Calcium Level 0.69
13.03 (1.50) 14.33 (0.95) 13.50 (n/a)
77.95 (5.91) 72.50 (6.61) 77.00 (n/a)
95.62 (50.68) 74.88 (38.00) 73.50 (89.47)
2.63 (1.71) 3.08 (1.62) 3.80 (n/a)
25.16 (2.32) 24.50 (1.91) 25.00 (n/a)
3.90 (n/a)
*p<0.05; **p<0.01
Abbreviations: ARI: acute respiratory illness; ILI: influenza-like illness
2.00 (n/a) 2.17 (0.26) 2.00 (n/a)
140.00 (n/a) 140.33 (4.51) 127.00 (n/a)
4.20 (n/a) 4.57 (0.84) 4.30 (n/a)
4.86 (1.48) 3.90 (n/a)
aBMI classification based on WHO and CDC criteria where underweight = <5th percentile, normal weight = 5th to <85th percentile, overweight = 85th to <95th 
percentile, obese = ≥ 95th percentile.
Totals/means are from admission laboratory data only. Numbers presented are total number of participants with corresponding percent in each dengue disease severity 
category for categorical characteristics or mean with correpsonding standard deviation for continuous characteristics. Characteristics with only one data point have 
standard deviation values of "n/a". χ-square tests were used to calcualte p-values for categorical characteristic variables. Fisher's exact tests were used in place of χ-sqaure 
tests when small cell frequencies were encountered. ANOVA tests were used to calculate p-values for continuous characteristic variables. 
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Table 7. Distribution of Conitnuous and Categorical Liver and Kidney Protein 
Levels; CDS 2011-2013, n=551 
 
 
Liver:
     Albumin:
Admission Level 3.66 1.15 0 (0%) 3 (100.00%)
Day 2 Level 5.4 1.52 0 (0%) 5 (100.00%)
     ALT:
Admission Level 82.28 49.88 78 (17.49%) 368 (82.51%)
Day 2 Level 78.02 62.93 17 (18.48%) 75 (81.52%)
Day 3 Level 73.29 51.93 8 (19.05%) 34 (80.95%)
Day 4 Level 101.13 79.49 3 (20.00%) 12 (80.00%)
Day 5 Level 4.86 2.41 7 (100.00%) 0 (0%)
Day 6 Level 3.5 2.12 2 (100.00%) 0 (0%)
Day 7 Level 2.67 2.89 3 (100.00%) 0 (0%)
     AST:
Admission Level 89.75 55.5 64 (14.35%) 382 (85.65%)
Day 2 Level 89.88 71.22 17 (18.48%) 75 (81.52%)
Day 3 Level 72.67 48.69 7 (16.67%) 35 (83.33%)
Day 4 Level 111.27 66.4 3 (20.00%) 12 (80.00%)
Day 5 Level 5.14 2.61 7 (100.00%) 0 (0%)
Day 6 Level 4.5 0.71 2 (100.00%) 0 (0%)
Day 7 Level 2.33 2.31 3 (100.00%) 0 (0%)
     Total Protein:
Admission Level 62.34 10.29 292 (75.06%) 97 (24.94%)
Day 2 Level 5.29 2.05 0 (0%) 17 (100.00%)
Day 3 Level 5.78 0.83 0 (0%) 9 (100.00%)
Day 5 Level 6.00 0 0 (0%) 2 (100.00%)
Kidney:
     Creatinine:
Admission Level 81.00 9.40 0 (0%) 6 (100.00%)
Day 2 Level 93.58 33.67 2 (16.67%) 10 (83.33%)
Day 3 Level 65.25 17.23 2 (50.00%) 2 (50.00%)
Day 4 Level 72.67 20.43 1 (33.33%) 2 (66.67%)
Day 5 Level 5.00 0.00 2 (100.00%) 0 (0%)
     Urea:
Admission Level 4.10 1.18 3 (100.00%) 0 (0%)
Day 2 Level 14.08 23.57 6 (75.00%) 2 (25.00%)
Day 3 Level 2.50 0.71 2 (100.00%) 0 (0%)
Day 4 Level 5.50 4.95 1 (50.00%) 1 (50.00%)
Day 5 Level 6.00 4.24 1 (50.00%) 1 (50.00%)
Abbreviations: SD, standard deviation; ALT: alanaine aminotransferase; AST: aspartate aminotransferase
Total (%) 
Abnormal LevelsMean SD
Total (%) 
Normal Levels
Percentages represent number of participants with analyzed protein level on each day of hospital stay divided by the total 
number of individuals with the analyzed protein level on the same day of hospital stay. Data presented only for days of 
hospital stay where ≥ 1 participant had analyzed protein levels. 
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Table 8. Distribution of Covariates by Liver Protein Levels; CDS 2011-2013, n=551 
 
 
 
 
 
 
 
                                                 
Characteristics Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
Age n/a 9.33 (3.06) n/a 7.83 (3.57) 7.99 (3.42) 0.71 7.66 (3.67) 8.02 (3.40) 0.44 8.03 (3.41) 7.28 (3.03) 0.05
Sex 0.0005** 0.79 1.00
Male 0 (0%) 2 (66.67%) n/a 54 (69.23%) 174 (47.28%) 34 (53.13%) 194 (50.79%) 149 (51.03%) 50 (51.55%)
Female 0 (0%) 1 (33.33%) n/a 24 (30.77%) 194 (52.72%) 30 (46.87%) 188 (49.21%) 143 (48.97%) 47 (48.45%)
BMIa 0.77 0.15 0.17
Underweight 0 (0%) 0 (0%) n/a 31 (39.74%) 162 (44.02%) 23 (35.94%) 170 (44.5%) 138 (47.26%) 39 (40.21%)
Normal weight 0 (0%) 2 (66.67%) n/a 38 (48.72%) 161 (43.75%) 33 (51.56%) 166 (43.46%) 119 (40.75%) 50 (51.55%)
Overweight 0 (0%) 0 (0%) n/a 5 (6.41%) 19 (5.16%) 6 (9.38%) 18 (4.71%) 13 (4.45%) 5 (5.15%)
Obese 0 (0%) 1 (33.33%) n/a 4 (5.13%) 26 (7.07%) 2 (3.13%) 28 (7.33%) 22 (7.53%) 3 (3.09%)
Prior NSAID Use 1.00 1.00 0.25
Yes 0 (0%) 0 (0%) n/a 0 (0%) 1 (0.27%) 0 (0%) 1 (0.26%) 0 (0%) 1 (1.03%)
No 0 (0%) 3 (100.00%) n/a 78 (100.00%) 366 (99.73%) 64 (100.00%) 380 (99.74%) 291 (100.00%) 96 (98.97%)
Clinical diagnosis ARI/ILI 0.08 0.06 0.58
Yes 0 (0%) 0 (0%) n/a 2 (2.56%) 1 (0.27%) 2 (3.13%) 1 (0.26%) 3 (1.03%) 0 (0%)
No 0 (0%) 3 (0%) n/a 76 (97.44%) 367 (99.73%) 62 (96.88%) 381 (99.74%) 289 (98.97%) 97 (100.00%)
Prior dengue virus infection 0.91 0.27 0.40
Yes 0 (0%) 0 (0%) n/a 0 (0%) 4 (1.90%) 0 (0%) 4 (1.86%) 3 (1.83%) 0 (0%)
No 0 (0%) 2 (100.00%) n/a 46 (100.00%) 207 (98.10%) 42 (100.00%) 211 (98.14%) 161 (98.17%) 48 (100.00%)
Infusion prior to admission 0.30 0.48 0.0007**
Yes 0 (0%) 2 (66.67%) n/a 31 (41.33%) 180 (50.85%) 26 (41.94%) 185 (50.41%) 134 (47.52%) 61 (67.78%)
No 0 (0%) 1 (33.33%) n/a 44 (58.67%) 174 (49.15%) 36 (58.06%) 182 (49.59%) 148 (52.48%) 29 (32.22%)
Leukocyte count n/a 5.07 (1.83) n/a 5.21 (2.94) 5.43 (3.36) 0.59 5.30 (2.91) 5.41 (3.35) 0.80 5.27 (3.22) 5.81 (3.23) 0.59
Lymphocyte count n/a 4.70 (4.75) n/a 2.01 (1.56) 1.98 (1.32) 0.84 2.09 (1.57) 1.97 (1.33) 0.50 1.92 (1.36) 2.20 (1.35) 0.09
Hematocrit percent n/a 41.33 (4.93) n/a 40.21 (3.90) 40.32 (4.88) 0.85 39.83 (4.10) 40.38 (4.81) 0.39 40.13 (4.58) 41.22 (4.71) 0.0454*
Platelet count n/a 69.67 (31.26) n/a 102.49 (53.26) 90.93 (47.75) 0.06 96.27 (59.09) 92.40 (47.03) 0.56 99.53 (49.36) 73.18 (43.46) <0.0001***
ALT AST Total Protein
Liver Protein Levels
Albumin
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Table 8. Distribution of Covariates by Liver Protein Levels; CDS 2011-2013, n=551 (cont.) 
 
 
 
 
                                                 
Characteristics Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
ALT AST Total Protein
Liver Protein Levels
Albumin
Neutrophil count n/a n/a n/a 2.70 (2.09) 2.59 (1.57) 0.60 2.75 (2.28) 2.58 (1.56) 0.51 2.59 (1.56) 2.87 (2.18) 0.18
Hemoglobin value n/a n/a n/a 12.94 (1.41) 13.04 (1.54) 0.64 12.78 (1.46) 13.06 (1.52) 0.20 12.91 (1.47) 13.30 (1.56) 0.0254*
Mean Corpuscular Volume n/a n/a n/a 76.70 (6.15) 77.90 (5.93) 0.13 76.61 (6.55) 77.86 (5.87) 0.16 78.29 (5.65) 76.56 (6.38) 0.0122*
Mean Corpuscular Hemoglobin n/a n/a n/a 24.67 (2.70) 25.18 (2.26) 0.11 24.52 (2.63) 25.18 (2.29) 0.06 25.20 (2.28) 24.77 (2.33) 0.11
Glucose level n/a 4.10 (n/a) n/a 3.90 (0.10) 4.44 (0.73) 0.24 3.90 (0.14) 4.39 (0.72) 0.37 3.95 (0.21) 3.90 (n/a) 0.88
Sodium level n/a 143.50 (0.71) n/a 136.67 (8.74) 140.00 (4.99) 0.41 141.50 (3.54) 138.82 (6.15) 0.57 n/a 127.00 (n/a) n/a
Potassium level n/a 3.90 (0.28) n/a 3.93 (0.47) 4.56 (0.72) 0.19 3.75 (0.49) 4.54 (0.68) 0.15 n/a 4.30 (n/a) n/a
Calcium level n/a 2.05 (0.21) n/a 2.05 (0.13) 2.16 (0.25) 0.49 2.08 (0.19) 2.15 (0.25) 0.71 2.20 (n/a) 2.00 (n/a) n/a
*p<0.05, **p<0.01, ***p<0.0001
aBMI classification based on WHO and CDC criteria where underweight = <5th percentile, normal weight = 5th to <85th percentile, overweight = 85th to <95th percentile, obese = ≥ 95th percentile.
Abbreviations: ARI: acute respiratory illness; ILI: influenza-like illness
Totals/means are from admission laboratory data only. Numbers presented are total number of participants with corresponding percent in each liver protein category for categorical characteristics or mean with corresponding 
standard deviation for continuous characteristics. Characteristics with only one data point have standard deviation values of "n/a". Normal and abnormal protein levels with characteristic values of "n/a" indicate missing data. χ-
square tests were used to calcualte p-values for categorical characteristic variables. Fisher's exact tests were used in place of χ-sqaure tests when small cell frequencies were encountered. ANOVA tests were used to calculate p-
values for continuous characteristic variables. P-values could not be calculated for comparison groups with <1 data point (indicated by value of "n/a" in p-value columns).
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Table 9. Distribution of Covariates by Liver Protein Levels; CDS 2011-2013, n=551 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
Characteristics
Age
Sex
Male
Female
BMIa
Underweight
Normal weight
Overweight
Obese
Prior NSAID Use
Yes
No
Clinical diagnosis ARI/ILI
Yes
No
Prior dengue virus infection
Yes
No
Infusion prior to admission
Yes
No
Leukocyte count
Creatinine
Kidney Protein Levelsb
Abnormal
Urea
Normal
9.83 (3.13)
1 (16.67%)
5 (83.33%)
2 (33.33%)
4 (66.67%)
0 (0%)
0 (0%)
0 (0%)
6 (100%)
0 (0%)
4 (66.67%)
2 (33.33%)
6 (100%)
0 (0%)
3 (100%)
8.07 (4.24) 4.90 (1.77)
1 (33.33%)
0 (0%)
2 (66.67%)
1 (33.33%)
8.67 (4.16)
3 (100%)
0 (0%)
0 (0%)
0 (0%)
3 (100%)
2 (66.67%)
2 (100%)
0 (0%)
3 (100%)
0 (0%)
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Table 9. Distribution of Covariates by Liver Protein Levels; CDS 2011-2013, n=551 
(cont.) 
 
 
 
 
                                                 
Characteristics
Creatinine
Kidney Protein Levelsb
Abnormal
Urea
Normal
Lymphocyte count
Hematocrit percent
Platelet count
Neutrophil count
Hemoglobin value
Mean Corpuscular Volume
Mean Corpuscular Hemoglobin
Glucose level
Sodium level
Potassium level
Calcium level
aBMI classification based on WHO and CDC criteria where underweight = <5th percentile, 
normal weight = 5th to <85th percentile, overweight = 85th to <95th percentile, obese = ≥ 95th 
percentile.
Totals/means are from admission laboratory data only. Numbers presented are total number of 
participants with corresponding percent in each liver protein category for categorical 
characteristics or mean with corresponding standard deviation for continuous characteristics. 
Normal or abnormal protein levels with characteristic values of "n/a" indicate missing data. P-
values could not be calculated as all comparison groups contained <1 data point.
2.83 (1.30)
45.17 (5.64)
52.50 (29.53)
n/a
n/a
2.15 (0.17) 2.03 (0.16)
3.83 (0.23)
144.00 (1.00)
41.00 (4.36)
n/a
n/a
5.08 (0.84)
141.50 (4.23)
4.42 (0.74)
2.20 (1.51)
4.35 (0.35)
n/a
n/a
n/a
n/a
Abbreviations: ARI: acute respiratory illness; ILI: influenza-like illness
63.67 (40.02)
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Table 10. Unadjusted and Multivariable Beta Estimates and 95% Confidence Interval (CI) of Dengue Disease Severity by 
Abnormal Liver Protein Levels; CDS 2011-2013, n=551 
 
 
Dengue Disease Severity Beta 95% CI Beta 95% CI Beta 95% CI Beta 95% CI Beta 95% CI Beta 95% CI Beta 95% CI Beta 95% CI
Dengue Fever 0 Referent 0 Referent 0 Referent 0 Referent 0 Referent 0 Referent 0 Referent 0 Referent
Severe Dengue -0.07 -0.12, -0.02 -0.08 -0.45, 0.29 -0.38 -2.26, 1.51 -18.02 -51.59, 15.55 1.83 -0.24, 3.90 -7.18 -49.57, 35.21 -7.09 -7.91, -6.28 7.14 1.15, 13.13
Unadjusted Adjustedc Unadjusted AdjusteddAdjustedbUnadjustedUnadjusted Adjusteda
Severe Dengue refers to clinical diagnosis with either dengue hemorrhagic fever or dengue shock syndrome. Linear mixed modeling was used to obtain beta estimates with corresponding 95% confidence intervals. Results expressed as the change in mean protein level (Beta) for 
those clinically diagnosed with severe dengue comapred to those clinically diagnosed with dengue fever. Covariates that produced a 20% or greater change in the beta coefficient for each liver protein level were retained in each adjusted model. Statistical significance is represented 
Total ProteinAlbumin Albumin ALT ALT AST AST Total Protein
aAdjusted for age, BMI, for prior infusion, leukocyte count, lymphocyte count, hematocrit percent, platelet count, neutrophil count, hemoglobin, mean corpuscular hemoglobin, and glucose, sodium, and calcium levels.
bAdjusted for age, BMI sex, prior infusion, leukocyte count, lymphocyte count, hematocrit percent, platelet count, hemoglobin, mean corpuscular hemoglobin, and glucose, sodium, and calcium levels.
cAdjusted for age, BMI, sex, prior infusion, leukocyte count, lymphocyte count, hematocrit percent, platelet count, neutrophil count, hemoglobin, mean corpuscular hemoglobin, and glucose, sodium, potassium and calcium levels.
dAdjusted for age, BMI, sex, platelet count, hematocrit percent, mean corpuscular volume, mean corpuscular hemoglobin, and glucose and potassium levels.
Abbreviations: ALT, alanine aminotransferase; AST: aspartate aminotransferase.
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Figure 1. Total Number of Participants with (Any) Abnormal Liver Protein Level 
by Day of Hospital Stay; CDS 2011-2013, n=551 
Data presented are total number of participants on each day of hospital stay who have one 
or more abnormal liver protein levels (i.e. albumin, ALT, AST, and/or total protein). 
Results are stratified by dengue disease severity. Abnormal liver protein level cut-points 
were adapted from the Harriet Lane Handbook, 21st Edition. Day 1 of hospital stay refers 
to day of admission. 
Abbreviations: DF, dengue fever. 
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Figure 2. Percent of Participants with (Any) Abnormal Liver Protein Level by Day 
of Hospital Stay; CDS 2011-2013, n=551 
Data presented are total number of participants with one or more abnormal liver protein 
levels (i.e. albumin, ALT, AST, and/or total protein) divided by the total number of 
participants in each dengue disease severity category to yield percent values. Results are 
stratified by dengue disease severity. Abnormal liver protein level cut-points were 
adapted from the Harriet Lane Handbook, 21st Edition. Day 1 of hospital stay refers to 
day of admission. 
Abbreviations: DF, dengue fever. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
1 2 3 4 5 6 7
79.61
12.72
7.02
2.19
0.00 0.00 0.22
57.89
31.58
6.32
5.26
2.11 0.00 0.00
Pe
rc
en
t D
en
gu
e 
Di
se
as
e 
Ca
te
go
ry
 w
ith
 A
ny
 
Ab
no
rm
al
 Li
ve
r P
ro
te
in
 Le
ve
l
Day of Hospital Stay
DF
Severe Dengue
 40 
 
 
 
 
 
Figure 3. Total Number of Participants with (Any) Abnormal Kidney Protein Level 
by Day of Hospital Stay; CDS 2011-2013, n=551 
Data presented are total number of participants on each day of hospital stay who have one 
or more abnormal kidney protein levels (i.e. creatinine and/or urea). No participants 
clinically diagnosed with DF had creatinine or urea levels in the abnormal range. 
Abnormal kidney protein level cut-points were adapted from the Harriet Lane Handbook, 
21st Edition. Day 1 of hospital stay refers to day of admission. 
Abbreviations: DF, dengue fever. 
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Figure 4. Percent of Participants with (Any) Abnormal Kidney Protein Level by 
Day of Hospital Stay; CDS 2011-2013, n=551 
Data presented are total number of participants with one or more abnormal kidney protein 
levels (i.e. creatinine or urea) divided by the total number of participants in each dengue 
disease severity category to yield percent values. Results are stratified by dengue disease 
severity. Abnormal kidney protein level cut-points were adapted from the Harriet Lane 
Handbook, 21st Edition. Day 1 of hospital stay refers to day of admission. 
Abbreviations: DF, dengue fever. 
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        a.               b. 
 
            c.        
         
  
 
Figure 5. Distribution of ALT Levels by Dengue Disease Severity; CDS 2011-2013, 
n=551 
Boxplots are presented to represent the median and deviation from the median for ALT 
levels on day of hospital admission (a), day 2 (b), and day 3 (c) of hospital stay, stratified 
by two-level dengue disease severity. ALT levels are expressed as IU/L.   
Abbreviations: DF, dengue fever; IU, International Units. 
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        a.               b. 
 
        c. 
 
Figure 6. Distribution of AST Levels by Dengue Disease Severity; CDS 2011-2013, 
n=551  
Boxplots are presented to represent the median and deviation from the median for AST 
levels on day of hospital admission (a), day 2 (b), and day 3 (c) of hospital stay, stratified 
by two-level dengue disease severity. AST levels are expressed as IU/L.   
Abbreviations: DF, dengue fever; IU, International Units. 
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